Nivolumab/Ipilimumab Showcases Prolonged Treatment-Free Survival in Advanced RCC
OncLive,
Over a 42-month period, the combination of nivolumab and ipilimumab induced a longer treatment-free survival compared with…
Over a 42-month period, the combination of nivolumab and ipilimumab induced a longer treatment-free survival compared with…
A longer treatment-free survival was seen in patients with advanced renal cell carcinoma who were treated with first-line…
(HealthDay News) — For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus…
HealthDay News — For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus…
FRIDAY, Dec. 3, 2021 (HealthDay News) — For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with…
(HealthDay)—For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus ipilimumab…
(HealthDay)—For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus ipilimumab…
News Professional FRIDAY, Dec. 3, 2021 -- For patients with advanced renal cell carcinoma (aRCC), those initiating treatment…
NEW YORK (Reuters Health) – For patients with advanced renal cell carcinoma (aRCC), upfront treatment with two immune-checkpoint…
NEW YORK (Reuters Health) - For patients with advanced renal cell carcinoma (aRCC), upfront treatment with two immune-checkpoint…
Bottom Line: Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo…
Patients with advancedrenal cell carcinomawho received the checkpoint inhibitor combination nivolumabplus ipilimumabexperienced…
Credit: CC0 Public Domain Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination…
Bottom Line: Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo…
American Association for Cancer Research Bottom Line: Patients with advanced renal cell carcinoma who received the checkpoint…